Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Expedia Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Expedia Group Inc trades at $256.86 (market cap $32.39B). The key difference: Expedia Group Inc is far larger — about 7.2× ACADIA Pharmaceuticals Inc.'s market cap, and Expedia Group Inc pays a 0.65% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EXPE | |
|---|---|---|
Market Cap | $4.49B | $32.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $301.31 |
52-Week Low | $20.06 | $176.09 |
Enterprise Value | $3.69B | $31.30B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Expedia Group (EXPE) trades at $269.87, up 0.44% with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported consistent earnings beats in recent quarters with Q1 2026 EPS of $1.96 exceeding expectations of $1.41. Revenue growth has been steady, climbing from $11.7B in 2022 to $14.7B in 2025, while maintaining robust profitability with a 90.27% gross margin. Recent developments include the CarTrawler acquisition and positive travel industry research positioning the company for continued growth.
EXPE presents a compelling investment case with analyst consensus price target of $281.75 representing 4.4% upside potential. The stock offers exposure to the resilient travel sector with improving operational efficiency and strong cash flow generation. Key risks include travel sector volatility and competitive pressures, but the company's technological innovation and market position provide defensive characteristics in the evolving travel landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
